Pfizer starts Omicron-specific COVID-19 vaccine trial
The Hindu
The trial will involve 1,420 people aged 18-55.
Pfizer and its partner BioNTech have begun enrolment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement on January 25.
Pfizer’s CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Analysis of doubling errors in typed text reveals common typographical mistakes due to repetition markers in the brain.
Discover the untold story of Elizabeth Magie, the forgotten inventor of Monopoly, and her fight for recognition and equality.
Lakmé Fashion Week 2025 showcased a shift towards thoughtful, sustainable fashion with a focus on craftsmanship and wearability.
Physicists develop innovative technique using carbon-dioxide lasers to detect radioactive materials from safe distances for national defence and emergency response.